Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy

2018 ◽  
Vol 48 (12) ◽  
pp. 956-966 ◽  
Author(s):  
Takeshi Terashima ◽  
Tatsuya Yamashita ◽  
Hajime Sunagozaka ◽  
Kuniaki Arai ◽  
Kazunori Kawaguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Functional Reserve ◽  
Sorafenib Treatment ◽  
Liver Functional Reserve

Liver functional reserve and survival after sunitinib therapy in cirrhotic patients with advanced hepatocellular carcinoma.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e14600-e14600
Author(s):  
M. Biolato ◽  
M. Basso ◽  
A. Cassano ◽  
C. Cefalo ◽  
L. Miele ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Functional Reserve ◽  
Liver Functional Reserve ◽  
Cirrhotic Patients

Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma

2020 ◽  
Vol 50 (7) ◽  
pp. 871-884 ◽  
Author(s):  
Takeshi Terashima ◽  
Tatsuya Yamashita ◽  
Noboru Takata ◽  
Tadashi Toyama ◽  
Tetsuro Shimakami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Comparative Analysis ◽  
Advanced Hepatocellular Carcinoma ◽  
Functional Reserve ◽  
Liver Functional Reserve

Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience

2017 ◽  
Vol 35 (6) ◽  
pp. 611-617 ◽  
Author(s):  
Kazuomi Ueshima ◽  
Naoshi Nishida ◽  
Masatoshi Kudo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Objective Response ◽  
Progression Free Survival ◽  
Sequential Therapy ◽  
Advanced Hepatocellular Carcinoma ◽  
Open Label ◽  
Effective Treatment Option ◽  
Sorafenib Treatment ◽  
Advanced Hcc ◽  
Grade 3

Objectives: Previously, no therapeutic agent has been known to improve the overall survival compared with placebo in patients with hepatocellular carcinoma (HCC), who have progressed after sorafenib. In this patient population, regorafenib was first demonstrated to confer a survival benefit in the RESORCE trial, and subsequently it was approved as a second-line treatment for patients with advanced HCC. An open-label expanded access program (EAP) of regorafenib was implemented for compassionate use. We investigated the efficacy and safety of regorafenib based on our experience of the RESORCE trial and the EAP. Methods: Data from 5 patients from the RESORCE trial and 6 from the EAP were analyzed retrospectively. All patients had tolerated prior sorafenib and were progressing during sorafenib treatment. Results: The median progression-free survival was 9.2 months (95% CI 2.3-16.1). One patient achieved a partial response and 7 achieved stable disease. The objective response rate was 9.1%, and the disease control rate was 72.7%. No treatment-associated mortalities were observed. Grade 3 hypophosphatemia was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively. All treatment-related adverse events were improved by reduction or interruption of regorafenib. Five patients showed decreased serum albumin levels. Conclusion: Sorafenib and regorafenib sequential therapy presents a safe and effective treatment option for patients with advanced HCC.

scholarly journals Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

2021 ◽  
Author(s):  
Osman Öcal ◽  
Kerstin Schütte ◽  
Juozas Kupčinskas ◽  
Egidijus Morkunas ◽  
Gabija Jurkeviciute ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Objective Response ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment ◽  
Post Hoc Analysis ◽  
Y90 Radioembolization ◽  
Baseline Values ◽  
Post Hoc

Abstract Purpose To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib. Methods A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response. Results Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 57.9 pg/mL most effectively predicted overall survival for IL-6 and IL-8, respectively. Patients with high IL-6 (HR, 4.1 [1.9–8.9], p < 0.001) and IL-8 (HR, 2.4 [1.2–4.7], p = 0.009) had significantly shorter overall survival than patients with low IL values. Multivariate analysis confirmed IL-6 (HR, 2.99 [1.22–7.3], p = 0.017) and IL-8 (HR, 2.19 [1.02–4.7], p = 0.044) as independent predictors of OS. Baseline IL-6 and IL-8 with respective cut-off values predicted objective response rates according to mRECIST in a subset of 42 patients with follow-up imaging available (IL-6, 46.6% vs. 19.2%, p = 0.007; IL-8, 50.0% vs. 17.4%, p = 0.011). Conclusion IL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.

scholarly journals Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients

2015 ◽  
pp. 3193
Author(s):  
Yoshiyuki Wada ◽  
Yuko Takami ◽  
Masaki Tateishi ◽  
Tomoki Ryu ◽  
Kazuhiro Mikagi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment ◽  
Initial Imaging ◽  
Imaging Response

Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors

2015 ◽  
Vol 33 (3) ◽  
pp. 729-739 ◽  
Author(s):  
Sadahisa Ogasawara ◽  
Tetsuhiro Chiba ◽  
Yoshihiko Ooka ◽  
Naoya Kanogawa ◽  
Tomoko Saito ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factors ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment

scholarly journals The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0146456 ◽  
Author(s):  
Yoshiyuki Wada ◽  
Yuko Takami ◽  
Masaki Tateishi ◽  
Tomoki Ryu ◽  
Kazuhiro Mikagi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Progressive Disease ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment

scholarly journals Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma

Medicine ◽  
2019 ◽  
Vol 98 (44) ◽  
pp. e17692 ◽  
Author(s):  
Shou-Wu Lee ◽  
Teng-Yu Lee ◽  
Yen-Chun Peng ◽  
Sheng-Shun Yang ◽  
Hong-Zen Yeh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chinese Patients ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment
Sign in / Sign up

Export Citation Format

Share Document